Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias.

Abstract

A prospective randomized study of androgen therapy in aplastic anaemia (AA) was performed: 2 androgens (fluoxymesterone and norethandrolone) at high (1 mg/kg/d) and low (0.2 mg/kg/d) dose were studied on 110 patients; and 4 androgens given at high doses were objectively compared in 125 other cases. When patients are matched for AA severity there is an obvious efficiency of the high-dose androgens in the survival of the less severe cases of aplastic anaemia and in their haematological improvement. The data further show that, among the 4 androgens tested, fluoxymesterone is the most efficient and stanozolol the least. We conclude that androgen therapy is truly efficient in moderately severe aplastic anaemia and that fluoxymesterone (1 mg/kg/d) for 18 months should be chosen as reference drug to any new androgen therapy assay.

• Journal: Scandinavian journal of haematology (Scand J Haematol) Vol. 36 Issue 4 Pg. 346-52 (Apr 1986) ISSN: 0036-553X [Print] Denmark
• PMID: 2872720 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Androgens
• Testosterone
• Stanozolol
• Fluoxymesterone
• testosterone undecanoate
• Norethandrolone

Topics

• Adult
• Aged
• Androgens (therapeutic use)
• Anemia, Aplastic (drug therapy)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Female
• Fluoxymesterone (therapeutic use)
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Norethandrolone (therapeutic use)
• Prospective Studies
• Random Allocation
• Stanozolol (therapeutic use)
• Structure-Activity Relationship
• Testosterone (analogs & derivatives, therapeutic use)